Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2024
IR News
2024 IR News
RSS
IR News
11.29.2024
【Updated】Corporate Governance Report
11.07.2024
Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema
11.07.2024
Santen Announces Share Buyback
11.07.2024
Santen Announces Cancellation of Treasury Shares
11.07.2024
Santen Announces Completion of Share Buyback
11.07.2024
Santen Reports the 2nd Quarter Fiscal 2024 Consolidated Performance
11.01.2024
Santen launches Rhopressa® ophthalmic solution 0.02% (netarsudil mesylate), in South Korea, for the treatment of patients with open-angle glaucoma or ocular hypertension
11.01.2024
Santen Announces Status of Share Buyback
10.09.2024
Santen Announces Corporate Volunteer Partnership with Be My Eyes
10.01.2024
Santen Announces Status of Share Buyback
09.30.2024
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
09.26.2024
Santen applies for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action for lowering intraocular pressure
09.18.2024
Santen Publishes its Annual Integrated Report “Santen Report 2024”
09.03.2024
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
09.02.2024
Santen Announces Status of Share Buyback
08.06.2024
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium
08.06.2024
Santen Reports the 1st Quarter Fiscal 2024 Consolidated Performance
08.01.2024
Santen Announces Status of Share Buyback
07.31.2024
Corporate Governance Report
07.22.2024
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
07.01.2024
Corporate Governance Report
07.01.2024
Santen Announces Status of Share Buyback
06.25.2024
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
06.03.2024
Notice of Corporate Officer Change
06.03.2024
Santen Announces Status of Share Buyback
05.22.2024
Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan
05.09.2024
Notice of Board of Director and Corporate Auditor Nominations
05.09.2024
Notice of Recording of Impairment Loss and Loss on Valuation of Financial Assets
05.09.2024
Santen Announces Share Buyback
05.09.2024
Santen Reports Fiscal 2023 Consolidated Performance
05.07.2024
Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis
04.17.2024
Santen and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
04.16.2024
Santen Positioned for Further Growth in China Following Completion of Santen Vision Park
03.26.2024
Santen obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis
03.25.2024
Santen Announces Change of Representative Director of the Board
03.25.2024
Santen Announces Cancellation of Treasury Shares
03.25.2024
Santen Announces Completion of Share Buyback
03.11.2024
Notice of Corporate Officer Changes
03.01.2024
Santen Announces Status of Share Buyback
02.28.2024
Eyedrops for slowing the progression of myopia: Santen files application for manufacturing and marketing approval STN1012700 / DE-127 (atropine sulfate hydrate ophthalmic solution) in Japan
02.08.2024
Revision of Dividend Forecast
02.08.2024
Santen Reports the 3rd Quarter Fiscal 2023 Consolidated Performance
02.01.2024
Santen Announces Status of Share Buyback
01.18.2024
Japan Approval Obtained for Ophthalmic VEGF inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
01.05.2024
Santen Announces Status of Share Buyback
2023 IR News
2020 IR News
2022 IR News
2019 IR News
2021 IR News
News Archive